Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma ; volume:80 ; number:11 ; day:21 ; month:7 ; year:2020 ; pages:1145 ; date:7.2020
Drugs ; 80, Heft 11 (21.7.2020), 1145, 7.2020
- Creator
-
Frampton, James E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-020-01356-2
- URN
-
urn:nbn:de:101:1-2020091419441118177303
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Frampton, James E.
- SpringerLink (Online service)
Other Objects (12)
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma